A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521868-35-00

Enrollment

Registered

2026-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score. This scale measures the severity of symptoms in people with schizophrenia.

Interventions

DRUGNBI-1117570

DRUGPlacebo for nbi-1117570

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score. This scale measures the severity of symptoms in people with schizophrenia.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 24, 2026